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Abstract
Background: Proteasomes control the level of endogenous unfolded proteins by degrading them in the proteolytic core.
Insufficient degradation due to altered protein structure or proteasome inhibition may trigger cell death. This study
examined the proteasome response to HAMLET, a partially unfolded protein-lipid complex, which is internalized by tumor
cells and triggers cell death.
Methodology/Principal Findings: HAMLET bound directly to isolated 20S proteasomes in vitro and in tumor cells significant
co-localization of HAMLET and 20S proteasomes was detected by confocal microscopy. This interaction was confirmed by
co-immunoprecipitation from extracts of HAMLET-treated tumor cells. HAMLET resisted in vitro degradation by proteasomal
enzymes and degradation by intact 20S proteasomes was slow compared to fatty acid-free, partially unfolded a-
lactalbumin. After a brief activation, HAMLET inhibited proteasome activity in vitro and in parallel a change in proteasome
structure occurred, with modifications of catalytic (b1 and b5) and structural subunits (a2, a3, a6 and b3). Proteasome
inhibition was confirmed in extracts from HAMLET-treated cells and there were indications of proteasome fragmentation in
HAMLET-treated cells.
Conclusions/Significance: The results suggest that internalized HAMLET is targeted to 20S proteasomes, that the complex
resists degradation, inhibits proteasome activity and perturbs proteasome structure. We speculate that perturbations of
proteasome structure might contribute to the cytotoxic effects of unfolded protein complexes that invade host cells.
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Introduction
Cellular quality control systems survey proteinsynthesis to ensure
that erratic or unfolded products are degraded. The proteasomes
are crucial for extra-lysosomal protein degradation taking place in
the barrel-shaped 20S proteasome core [1–4]. The proteasome
response to endogenous unfolded proteins has been extensively
studied and proteasome inhibition and the failure to eliminate
erratic proteins is a well-known cause of amyloid formation and
disease [5,6]. In addition, the disease-causing prion protein
oligomers were recently shown to inhibit the 26S proteasome [7]
but except for this study, little is known about unfolded extracellular
proteins that enter target cells, and about the involvement of
proteasomes in the cytotoxic response to such proteins.
HAMLET (human a-lactalbumin made lethal to tumor cells) is
a protein-lipid complex that kills tumor cells [8,9] and shows
promising activity in vivo [10,11]. Intra-cranial infusion of
HAMLET prolonged survival in rats carrying human glioblastoma
xenografts [11] and intra-vesical HAMLET inoculation in bladder
cancer patients caused rapid shedding of tumor cells and a
reduction in tumor size [10]. Topical HAMLET application
removed skin papillomas in a placebo-controlled clinical study
[12]. The mechanism(s) of tumor cell death are not fully
understood, however.
Mature, folded a-lactalbumin acts as a coenzyme in lactose
synthesis [13–15] but partially unfolded a-lactalbumin forms
HAMLET by incorporating oleic acid [9]. The fatty acid cofactor
is essential for the tumoricidal activity since it helps maintain the
partially unfolded state in cellular environments [9,16]. The
tendency of a-lactalbumin to form stable folding intermediates is
well-known [17–19] but until the discovery of HAMLET, changes
in tertiary structure had not been proposed to alter the function of
PLoS ONE | www.plosone.org 1 April 2009 | Volume 4 | Issue 4 | e5229the protein. Structural studies have suggested that the conforma-
tional change of a-lactalbumin to a partially unfolded state is
necessary for the tumoricidal effect of HAMLET [16].
While in vitro studies have suggested that 20S proteasomes
degrade partially unfolded a-lactalbumin [20], cellular distribution
studies have shown that HAMLET accumulates in tumor cells,
suggesting that the mechanisms used by these cells to digest
unfolded a-lactalbumin are inefficient against HAMLET. We
hypothesized that internalized HAMLET might be identified as
partially unfolded a-lactalbumin and targeted to the proteasomes
for degradation [21] but that bound oleic acid might reduce the
sensitivity of partially unfolded a-lactalbumin to proteasome
degradation, making the HAMLET complex potentially toxic
for the proteasome.
This study examined if HAMLET interacts with and modifies
tumor cell proteasomes. The results suggest that HAMLET
interacts directly with 20S proteasomes, modifies their structure
and inhibits their activity.
Results
a-Lactalbumin is secreted by the mammary gland as a mature,
folded protein but can unfold by releasing Ca
2+ [22–24].
Extracellular unfolding can occur for example at low pH [25] in
environments like the stomach. To produce the HAMLET complex
in the laboratory, native a-lactalbumin is partially unfolded with
EDTA totheapostate andthen converted toHAMLET onan oleic
acid-preconditioned ion exchange matrix (Figure 1A) [9]. The fatty
acid stabilizestheproteininthe partially unfolded state,asshown by
near-UV CD spectroscopy (Figure 1B) [9].
The tumoricidal activity of HAMLET is shown in Figure 1C.
Human glioma cells and kidney carcinoma cells died rapidly in
response to HAMLET (34 mM) but normal differentiated cells
from the same tissues were resistant to the lethal effect (Figure 1C).
The internalization of HAMLET by tumor cells is visualized in
Figure 1D, using Alexa Fluor 568-labeled HAMLET (34 mM,
1 hour) in confocal microscopy. Tumor cells (A549) showed strong
intracellular staining after 1 hour and the cells changed morphol-
ogy and died. Native a-lactalbumin bound less efficiently than
HAMLET to the tumor cell surface, only small amounts were
internalized and the cells remained viable (Figure 1D). The
difference in uptake between HAMLET and a-lactalbumin was
quantified by flow cytometry. In tumor cells, there was a ,50 fold
difference in uptake after 1 hour between HAMLET and a-
lactalbumin (Figure 1E). There was also a marked difference in
HAMLET uptake measured by confocal microscopy between
tumor cells and normal cells of the same tissue origin. Rapid
internalization of HAMLET was detected in glioblastoma cells
(D54) and kidney carcinoma cells (A498) but not in normal kidney
epithelial cells (HRTEC). Normal astrocytes internalized small
amounts of HAMLET (data not shown).
HAMLET interacts with 20S proteasomes
To examine the in vitro interaction between HAMLET and 20S
proteasomes, intact 20S proteasomes (6 mg) were denatured and the
subunits were separated by SDS-PAGE and blotted onto PVDF
membranes. The membranes were overlaid with HAMLET
(0.14 mM) and stained with polyclonal anti-a-lactalbumin antibod-
ies.HAMLETwasshowntobindtoproteasome subunitsranging in
molecular weight from about 22–30 kDa (Figure 2A, left panel).
Primary and secondary antibody controls were negative. The in vitro
binding was confirmed by overlay of the blotted membranes with
radio-labeled HAMLET (Figure 2A, right panel). These results
suggest that HAMLET and 20S proteasome subunits can interact.
Further evidence of the binding of HAMLET to proteasome
subunits was obtained using a protein array. Arrays probed with
HAMLET were compared to negative controls without HAM-
LET. One of the top-scoring hits, with a Z-score of 6.54, was
proteasome subunit b5 (Figure 2B). This hit showed very low
variation between assays (coefficient of variation 8%) and replicate
spots (coefficient of variation 1%). Proteasomal subunits a1, 3 and
6 and b3 also showed increasing signal intensity with rising
HAMLET concentrations although they did not reach the
statistical threshold used to define a positive hit.
To examine if HAMLET interacts with 20S proteasomes in
tumor cells co-immunoprecipitation was used. A549 cells were
treated with HAMLET (34 mM, 1 hour), lysed and HAMLET
and associated proteins were precipitated from the lysates with
anti-a-lactalbumin antibodies. Lysates and precipitates were
examined for the presence for 20S proteasomes by Western blots
with antibodies against the 20S core subunits (a5, a7, b1, b5, b5i
and b7). A very weak band of ,30 kDa was recognized in the
precipitate from HAMLET-treated cells (Figure 2C). In addition
the antibodies against the 20S core subunits recognized bands of
,60 kDa in the lysate and precipitate from HAMLET-treated
cells. These bands could not be identified but might represent
complexes of HAMLET and 20S proteasomes.
The interaction of HAMLET with 20S proteasomes was
visualized by confocal microscopy (Figure 2D). A549 cells on
microscope slides were treated with Alexa Fluor 568-labeled
HAMLET (34 mM, 1 hour), fixed and stained with antibodies
against the 20S core subunits. Co-localization of HAMLET and
20S proteasomes was detected in the cell periphery (65% co-
localization) and throughout the cytoplasm of adherent cells (64%
co-localization, Figure 2D).
Resistance of HAMLET to degradation by proteasomal
enzymes
The sensitivity to proteolytic degradation was compared
between HAMLET, native a-lactalbumin and partially unfolded,
fatty acid-free a-lactalbumin (EDTA-treated). The proteins were
exposed to trypsin or chymotrypsin, samples were obtained after
5 minutes and at various time points until 54 hours and
fragmentation was examined by SDS-PAGE. Partially unfolded
a-lactalbumin was completely degraded after 5 minutes exposure
to trypsin (Figure 3A) or chymotrypsin (Figure 3B). HAMLET
started to degrade after 30 minutes exposure to trypsin and after
1 hour exposure to chymotrypsin but complete degradation
required at least 2 hours for chymotrypsin and 6 hours for trypsin
(see arrows in Figure 3A, B). The native protein was resistant to
degradation and remained intact after 54 and 29 hours exposure
to trypsin and chymotrypsin, respectively.
The sensitivity of HAMLET to degradation was further
examined by in vitro incubation of HAMLET or partially unfolded
EDTA-treated a-lactalbumin (7 mM) with active 20S proteasomes
(6 mg) for 2 hours, followed by SDS-PAGE and silver staining. Two
different batches of HAMLET and a-lactalbumin were used. Both
of the two EDTA-treated, partially unfolded a-lactalbumin samples
were degraded after 2 hours and degradation was blocked by the
chymotrypsin inhibitor MG132. In contrast, no degradation of the
HAMLET samples was detected (Figure 3C). The results suggested
that HAMLET is more resistant to proteolytic degradation than
partially unfolded a-lactalbumin protein without oleic acid.
Effects of HAMLET on proteasome activity
To examine if HAMLET influenced proteasome function, we
quantified the proteasome activity in vitro, using isolated 20S
proteasomes (200 ng) and chromogenic substrates (LLVY-AMC,
HAMLET-Proteasome Interaction
PLoS ONE | www.plosone.org 2 April 2009 | Volume 4 | Issue 4 | e5229Figure 1. HAMLET is a complex of partially unfolded a-lactalbumin and oleic acid. (A) HAMLET is formed when native a-lactalbumin
releases the strongly bound Ca
2+ and exposes a fatty-acid binding site, which permits oleic acid (C18:1, 9 cis) to interact and stabilize the partially
unfolded state. The figure was generated using the crystal structure of human a-lactalbumin [39] and MOLMOL 2K.2 [40]. (B) Near-UV CD spectra
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substrate cleavage in the control and this activity was inhibited by
MG132 (50 mM, Figure 4A). HAMLET caused a low, initial burst
of proteasome activity lasting about 10 minutes but subsequently
HAMLET acted as a partial proteasome inhibitor compared to
the control (Figure 4A). The results indicated that HAMLET
impaired the catalytic activity of the proteasome core. This effect
was confirmed in extracts from HAMLET-treated A549 carcino-
ma cells (34 mM, 1, 3 and 6 hours). A significant reduction in
proteasome activity was detected after 3 and 6 hours of HAMLET
treatment (Figure 4B, p,0.01, 6 hours).
Structural modifications of 20S proteasomes
To examine if HAMLET might alter proteasome structure,
HAMLET (7 mM) was mixed with intact 20S proteasomes (6 mg) in
vitro for 20 minutes and the samples were run on SDS-PAGE (12%
gel) under denaturing conditions. Structural modifications of the
proteasomes were detected by Amido black staining and altered
bands were trypsinized and identified by mass spectrometry
(Figure 5A). Four new bands were identified (see arrows,
Figure 5A). Band 1 contained the structural a3 subunit and the
a6 subunit that contains the nuclear localization sequence KKXK.
Band 2 contained the structural a2 subunit and band 3 the catalytic
b3 subunit. Band 4 contained a mixture of the catalytic subunits b1
with peptidyl glutamyl hydrolyzing activity and b5 with chymo-
trypsin-like activity. The observed protein matches were significant
(p,0.001). In order to investigate if autocatalytic chymotrypsin
activity was responsible for the proteasome fragmentation, non-
tryptic peptide masses were searched against semi-chymotrypsin
cleavages using the FindPept program. One peptide from the a2
subunit was matched (data not shown), suggesting that the changes
in proteasome structure might arise from both chymotrypsin-
dependent and other potentially autocatalytic activities.
Proteasome fragmentation in response to HAMLET was further
examined by Western blot (4–12% gel) (Figure 5B). Antibodies
against the 20S proteasome core subunits recognized a new
proteasome band of about 26 kDa and one of about 20 kDa (see
arrows, Figure 5B).
The change in 20S proteasome structure was confirmed by mass
spectrometry analysis of in vitro mixtures of HAMLET (7 mM) and
proteasomes (6 mg) (Figure 5C). The major difference between the
spectra is the decreased relative peak height for masses below
23.6 kDa. Minor other differences were observed. However, the
mass accuracy and resolution did not allow identification of
individual subunits based on mass alone.
Changes in proteasome structure in tumor cells
Confocal microscopy was used to visualize the change in 20S
proteasomes structure, following HAMLET treatment. A increase
in staining of 20S proteasome core subunits was observed after
HAMLET treatment suggesting that the epitopes targeted by the
polyclonal antibodies became more accessible (Figure 6A, B). This
effect was inhibited by MG132 (Figure 6C). The effect was specific
for HAMLET, as a-lactalbumin treatment did not alter proteasome
staining (data not shown). A similar increase in staining after
HAMLET treatment was observed using anti-b1 subunit antibodies
(Figure 6A, B). In contrast, when using the polyclonal b5-subunit
antibody, we observed a decrease in stainingconsistent with a loss of
this subunit after HAMLET treatment (Figure 6A, B).
Alterations in proteasome structure were further examined by
Western blots of total cell extracts from HAMLET-treated A549
cells (34 mM for 1 or 6 hours). In the control one main band of
approximately 20 kDa was detected using antibodies against the
20S proteasome core subunits (Figure 6D). After 6 hours of
HAMLET treatment, the intensity of this band was reduced.
The results of confocal microscopy and Western blot experi-
ments suggest that the structure of 20S proteasomes is modified in
response to HAMLET.
Discussion
Partially unfolded proteins are usually degraded in the
producing cell and the native, folded species is secreted or used
for diverse intracellular functions. In some cases, however, folding
is prevented by structural anomalies. HAMLET exemplifies a
third alternative where a native, secreted protein readily unfolds in
response to new environments and where this partially unfolded
species then is internalized by target cells. In the case of HAMLET
the partially unfolded protein is a-lactalbumin, which is prevented
from reversion to the native state by binding to a fatty acid
cofactor. We show here that HAMLET invades tumor cells and
challenges the machinery that normally degrades partially
unfolded proteins. The results suggest that HAMLET is
recognized by the 20S proteasomes but resists degradation and
forces the proteasomes to undergo structural modifications that
inhibit their activity. We speculate that this process might
contribute to the accumulation of HAMLET in tumor cells and
to the cytotoxic response in tumor cells.
Unfolded proteins are a known threat to tissue homeostasis and
yet, misfolding accompanies normal protein synthesis [3,26,27].
About 40% of newly synthesized peptides have errors, which
prevent them from folding to the native state and many of these
peptides are targeted to the proteasomes and successfully degraded
[28]. Mutations may permanently hinder normal folding and in
this case the risk of pathology increases as the unfolded proteins
accumulate in the tissues causing aggregation and formation of
insoluble fibrils and plaques [27]. One such protein is the amyloid
beta-protein (A beta) and its precursor found in neurofibrillary
tangle-containing neurons. A beta has been shown to selectively
inhibit the chymotrypsin-like activity of the 20S proteasome
leading to formation of inclusion bodies in neurodegenerative
disorders such as Alzheimer’s disease and Down’s syndrome [5,6].
The prion protein is thought to unfold extracellularly and the
prions are cytotoxic, in part, by invading target cells [29,30].
Disease-causing Prp
sc peptides were recently shown to inhibit the
activity of 26S proteasomes, which require ubiquitin tags for
degradation [7]. Pre-incubation with an antibody specific for
aggregation-prone intermediates abrogated this inhibition.
HAMLET represents a different type of unfolded protein species
but shares some features with the prions. The native protein is
secreted by the mammary gland but can unfold in response to
environmental change such as low pH in the stomach. Partially
were recorded in sodium phosphate buffer without EDTA. Native a-lactalbumin showed the expected minimum at 270 nm arising from the tyrosine
and a maximum at 293 nm arising from the tryptophan residues. In HAMLET, a-lactalbumin showed a loss of signal at 270 nm and at 293 nm, typical
of partial unfolding [9,16]. Apo a-lactalbumin was obtained by EDTA treatment and showed a similar loss of signal. (C) Effect of HAMLET on tumor
cells and healthy cells. Glioblastoma cells and kidney carcinoma cells treated with HAMLET (34 mM, 1 and 3 hours) died while normal astrocytes and
renal epithelial cells (HRTEC) remained viable. (D) Difference in uptake of HAMLET and a-lactalbumin by tumor cells. Lung carcinoma cells (A549)
were exposed to 34 mM of Alexa Fluor 568-labeled HAMLET or a-lactalbumin (both red). (E) Quantification by flow cytometry of HAMLET or a-
lactalbumin uptake by A549 cells (N=10,000) after 1 and 3 hours of incubation.
doi:10.1371/journal.pone.0005229.g001
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under physiological conditions but the oleic acid-bound form in
HAMLET remains stably unfolded and the complex invades tumor
cells. This study shows that HAMLET binds directly to several
subunits within the 20S proteasome. Such direct interactions of
partially unfolded protein complexes and the proteasome have not
previously been demonstrated. As a result, large amounts of
partially unfolded a-lactalbumin may resist proteasome degrada-
tion, leading to HAMLET accumulation in tumor cells.
In addition, HAMLET triggered structural modifications of the
20S proteasomes. For example, HAMLET triggered the fragmen-
tation of the a3 subunit, which is a key regulator of the proteasome
gate. Previously, conformational changes of proteasome a subunits
have been described but proteasome fragmentation in response to
cellular agonists have not been reported. Co-crystallization studies
of yeast 20S proteasomes with the 11S activator from Trypanosoma
brusei suggested that the 11S activator opens the proteasome
entrance port by modifications of the a subunits [31]. Functional
studies in yeast confirmed this effect [32]. Furthermore, an N-
terminal deletion of the a3 subunit has been shown to abolish
proteasomal peptidase activity and to disorder the remaining pore
residues [33]. The present study detected a structural modification
of the a3 subunit, suggesting that direct effects of HAMLET on
this subunit might cause further disordering of the proteasome. In
addition, the structural a2, a6 and b3 subunits were modified, as
were the catalytic b1 and b5 subunits. This gradual disintegration
of the proteasome might include the 26S proteasome, especially
since we also observed fragmentation of the 19S Rpt3 ATPase
(data not shown). By confocal microscopy, alterations in subunit
staining were observed after HAMLET treatment. There was a
loss of b5 staining, compatible with the mass spectrometry data. In
parallel, there was an increase in staining of b1 and other core
subunits, suggesting structural modifications that make those
subunits more available to the antibodies used.
We speculate that the inhibition of proteasome activity by
HAMLET may be explained by the structural changes in the
proteasome but the molecular basis of structural proteasome
modification in response to HAMLET is not clear. Two scenarios
may be proposed. Firstly, the proteasomes may self-destruct due to
a dysfunctional interaction with the target. The protease resistance
of the HAMLET complex might result in a prolonged enzymatic
attack that eventually rebounds to include the proteasome itself.
This hypothesis was supported by the mass spectrometry analysis
since a chymotrypsin-cleaved fragment of proteasomal a2 subunit
was observed after HAMLET treatment. Secondly, the protea-
some structure might be modified by oleic acid as proteasomes are
activated by low concentrations of surface-active molecules
including detergents. Watanabe et al. have shown that low
concentrations of oleic acid, linoleic and linolenic acids activate
the chymotrypsin and peptidylgutamyl hydrolyzing activity of the
proteasomes [34]. The lipid cofactor in HAMLET may thus
participate in proteasome activation and possibly help to disturb
proteasome structure.
So far, the failure to degrade unfolded proteins has mainly been
described as a cause of cytotoxicity and disease. HAMLET has
beneficial effects, however, due to its effects on tumor cells. The
present study proposes that the entry of exogenous HAMLET
exposes tumor cells to large amounts of partially unfolded a-
lactalbumin and that the destructive proteasome response to
HAMLET occurs mainly in tumor cells. While cellular response
mechanisms might be shared between HAMLET and other
unfolded protein species such as amyloid, there are major
differences in the cellular spectrum. HAMLET appears to have
struck a balance between beneficial and destructive mechanisms,
which may be a key to tumor cell death.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Medical Ethics Committee of the Lund University Medical
Faculty, Lund, Sweden (decision number LU 456-96). Samples
were obtained after written informed consent from the parents.
Preparation of a2lactalbumin and HAMLET
a-Lactalbumin was purified from human milk and HAMLET
was produced from a-lactalbumin as described [9]. Briefly, a-
lactalbumin was partially unfolded by EDTA treatment and
bound to oleic acid by ion exchange chromatography on a DEAE-
Trisacryl M column (Pall BioSepra, Cergy-Saint-Christophe,
France) preconditioned with oleic acid. When required, HAM-
LET or a-lactalbumin was conjugated to Alexa Fluor 568
according to the manufacturer’s instructions (Molecular Probes
Inc., Eugene, OR, USA).
Cells
The human lung carcinoma cell line A549 (CCL 185, ATCC,
Manassas, VA, USA), the human glioblastoma cell line D54 (gift
from Darrel D-Bigner, Duke University, Durham, NC, USA) and
the human kidney carcinoma cell line A498 (HTB44, ATCC) were
cultured as described [8,11,35]. Human non-transformed astrocytes
(CC 2565, Cambrex, La Jolla, CA, USA) were cultured according
to the manufacturer’s instructions. Human renal epithelial cells
(HRTEC) were kindly provided by Dr. Diana Karpman (Lund
University, Lund, Sweden). HRTEC were isolated from the kidney
of a 3-year old boy as described [36] after written informed consent
from the parents. IRB approval was obtained from the Medical
Ethics Committee of the Lund University Medical Faculty, Lund,
Sweden (decision number LU 456-96).
Near-UV Circular dichroism spectroscopy
Lyophilized material was dissolved in 5 mM Tris, pH 8.5 to
70 mM. Near-UV CD spectra were collected at 25uC between 240
and 320 nm. The wavelength step was 1 nm, the response time
was 8 sec and the scan rate 10 nm/min. An average of six scans is
Figure 2. Interaction of HAMLET with proteasomes in vitro and in tumor cells. (A) Binding of HAMLET to 20S proteasome subunits. 20S
proteasomes were denatured, separated by SDS-PAGE and stained with Amido black or silver staining or blotted onto PVDF membranes. Left panels:
Membranes were overlaid with 0.14 mM HAMLET and binding was detected by immunoblot using anti-a-lactalbumin antibodies. Right panels:
Membranes were overlayed with
125I-HAMLET and binding was detected by autoradiography. (B) Binding of HAMLET to 20S proteasome b5 subunit
on a protein array. Protein arrays were probed with Alexa Fluor 568-labeled HAMLET and fluorescence intensity was measured. HAMLET bound to the
20S proteasome b5 subunit in a concentration-dependent manner. (C) Co-immunoprecipitation of lysates from HAMLET-treated A549 cells (34 mM,
1 hour) with anti-a-lactalbumin antibodies (IP anti-a-lact) or no antibodies (IP mock). Lysates and precipitates were examined by Western Blot using
antibodies against the 20S proteasome core subunits. A very weak band was detected at ,30 kDa. (D) Confocal images showing co-localization of
Alexa Fluor 568-labeled HAMLET (34 mM, 1 hour) and 20S proteasomes (antibody against 20S proteasome core subunits) in the cell periphery and
cytoplasm of A549 cells.
doi:10.1371/journal.pone.0005229.g002
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26d-
mol
21, was calculated as previously described [37].
Cell death assay
Trypan blue exclusion was used to measure viability. Cell
suspension was mixed 3:1 with 0.2% Trypan blue (Chroma
Gesellschaft Schmid & Co, Stuttgart, Germany) in 0.9% NaCl and
the number of living cells was counted in a Bu ¨rker chamber.
Confocal fluorescence microscopy
Cells were detached from tissue culture flasks with Versene
buffer (140 mM NaCl, 2.4 mM KCl, 8 mM Na2HPO4, 1.6 mM
Figure 3. Resistance of HAMLET to degradation by proteasomal enzymes. (A, B) HAMLET, partially unfolded a-lactalbumin (apo a-
lactalbumin) or native a-lactalbumin was exposed to trypsin (E:S 1:50, by weight) (A) or chymotrypsin (E:S 1:100, by weight) (B) in vitro and fragments
were detected by SDS-PAGE. Native a-lactalbumin was in 200 mM calcium acetate whereas partially unfolded a-lactalbumin was in 200 mM EDTA.
Arrows indicate time points when all HAMLET was degraded. (C) HAMLET or partially unfolded a-lactalbumin (apo a-lact) (both 7 mM) were mixed
with 6 mg of human erythrocyte 20S proteasomes and incubated for 2 hours at 37uC. The proteins were separated by SDS-PAGE and visualized by
silver staining. MG132 was used to inhibit proteasome activity. The arrows indicate the molecular sizes of full length apo a-lactalbumin/HAMLET
(14 kDa) and a smaller fragment (,7 kDa).
doi:10.1371/journal.pone.0005229.g003
HAMLET-Proteasome Interaction
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slides (Nalge Nunc, Naperville, IL, USA) overnight (50,000 cells/
well). Cells were then washed twice with PBS, incubated at 37uC
with 34 mM HAMLET (34 mM unlabelled HAMLET or 7 mM
Alexa Fluor 568-labeled HAMLET and 27 mM unlabeled
HAMLET) or 34 mM a-lactalbumin (34 mM unlabelled a-
lactalbumin or 7 mM Alexa Fluor 568-labeled a-lactalbumin and
27 mM unlabeled a-lactalbumin) in serum-free medium. The
slides were washed twice in PBS and fixed in 4% paraformalde-
hyde. For antibody stainings cells were then permeabilized in
0.1% saponin, 5% FCS, PBS for 20 minutes and incubated with
polyclonal rabbit antibodies against the core subunits (a5, a7, b1,
b5, b5i and b7) of the 20S proteasome (1:100–500, Cat
No. PW8155, BioMol, Denvon, UK), monoclonal mouse anti-b1
antibodies (1:100, Cat No. PW8140, BioMol), polyclonal rabbit
anti-b5 antibodies (1:100, Cat No. PW8895, BioMol) and
secondary goat anti-rabbit-Alexa Fluor 488 or goat anti-mouse-
Alexa Fluor 488 antibodies (both 1:500–1000, Molecular Probes
Inc.). Cells were examined by confocal microscopy in an LSM 510
META system (Carl Zeiss, Jena, Germany). Confocal scans were
Figure 4. HAMLET inhibits proteasome activity. (A) Proteasome activity was monitored in vitro as chymotrypsin-dependent suc-LLVY-AMC
cleavage (50 mM) over time and MG132 was used as proteasome inhibitor. Except for the first 10 minutes HAMLET reduced proteasome activity
compared to the control. (B) Inhibition of proteasome activity in A549 cells. Cytoplasmic extracts were prepared from cells treated with HAMLET or
native a-lactalbumin (34 mM) after 1, 3 and 6 hours of incubation and enzymatic activity was quantified by suc-LLVY-AMC cleavage (50 mM). MG132
was used to inhibit proteasome function.
doi:10.1371/journal.pone.0005229.g004
HAMLET-Proteasome Interaction
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sections were set to 1.0 mm. Quantification of fluorescence
intensity and co-localization analysis was performed using the
LSM META 510 software package (Carl Zeiss).
Flow cytometry
10
5 A549 cells in suspension were treated with 7 mM Alexa
Fluor 568-labeled HAMLET and 27 mM unlabeled HAMLET or
7 mM Alexa Fluor 568-labeled a-lactalbumin and 27 mM
unlabeled a-lactalbumin. After 1 hour of HAMLET treatment
5% FCS was added. The binding and uptake of HAMLET or a-
lactalbumin was quantified by flow cytometry using a Becton
Dickinson FACScalibur cytometer and CellQuest Pro Software
(BD Biosciences, San Jose, CA, USA).
In vitro binding assay of HAMLET and 20S proteasomes
20S proteasomes (6 mg, BioMol) were denatured and separated
by SDS-PAGE (NuPAGE 12% Bis-Tris or 4–12% Bis-Tris gels,
Invitrogen, Carlsbad, CA, USA) and stained with Amido black or
silver staining. Separate gels were blotted to PVDF-Plus
membranes (GE Osmonics, Minnetonka, MN, USA), which were
blocked 15 minutes with Sat-1 buffer (6.1 g/l ethanolamine, 9 g/l
glycine, 10 g/l polyvinylpirolidone, 25% methanol) and 15 min
with Sat-2 buffer (6.1 g/l ethanolamine, 9 g/l glycine, 1.25 g/l
Tween-20, 5 g/l gelatine hydrolysate, 25% methanol) and
incubated with HAMLET (0.14 mM) over night at room
temperature. The membranes were then blocked in 2% BSA
and incubated with polyclonal rabbit anti-a-lactalbumin antibod-
ies (1:500, Sigma-Aldrich, St. Louis, MO, USA) and HRP-
conjugated goat anti-rabbit antibodies (1:500, DAKO Cytoma-
tion, Glostrup, Denmark). Bound antibodies were detected with
ECL Plus Western Blotting Reagent (GE Healthcare, Little
Chalfont, UK) and GelDoc equipment (Bio-Rad Laboratories,
Hercules, CA, USA). Alternatively, membranes were incubated
with
125I-labelled HAMLET which was detected by autoradiog-
raphy.
Protein array
The interaction between HAMLET and more than 8,000
human proteins was investigated with a ProtoArrayH Human
Protein Microarrays v4.0 using Invitrogen’s Protein-Protein
Interaction Profiling Service. Experiments were conducted at
Invitrogen (Branford, CT, USA) as previously described [38].
Briefly, arrays were probed with Alexa Fluor 568-labelled
HAMLET in two different concentrations (5 and 50 ng/ml) in
duplicate. Interactions between HAMLET and the immobilized
proteins on the arrays were evaluated by their Z-Score rank within
the array and compared to the interactions observed on the
negative control array. A total of eighty-seven proteins were
identified as candidate interactors with HAMLET.
Co-immunoprecipitation
A549 cells were washed, diluted to 10
6/ml in serum-free
medium and treated with HAMLET (36 mM) for 1 hour in 24-
well culture plates (TPP, Trasadingen, Switzerland). After
treatment cells were detached with Versene buffer (140 mM
NaCl, 2.4 mM KCl, 8 mM Na2HPO4, 1.6 mM KH2PO4,
0.5 mM EDTA, pH 7.2), collected by centrifugation (4006g,
8 minutes) and lysed in ice-cold NP-40 buffer (20 mM Tris-HCl,
pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) supplement-
ed with Complete protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany). Lysates were incubated for 1 hour at 4uC
with washed rec-Protein G-Sepharose 4B Conjugate beads
(Invitrogen) to clear unspecifically binding proteins. After that a-
lactalbumin antibodies (Cat No. A10-128A, Bethyl Laboratories,
Montgomery, TX, USA) were added to half of the lysate (5 mg
antibodies/ml lysate), the other half was used as control and both
lysates were incubated with gentle agitation at 4uC. After 1 hour
washed Protein G beads were added and the incubation was
continued overnight. Beads with bound proteins were collected by
centrifugation (12,0006g, 30 sec) and washed 3 times in lysis
buffer. To release bound proteins beads were boiled for 5 minutes
in LDS sample buffer (Invitrogen) with DTT (100 mM). Proteins
were separated by SDS-PAGE and blotted onto PVDF-Plus
membranes (GE Osmonics). Membranes were blocked with BSA
and incubated with polyclonal rabbit antibodies against the core
subunits (a5, a7, b1, b5, b5i and b7) of the 20S proteasome
(1:2,000, Cat No. PW8155, BioMol) and HRP-conjugated swine
anti-rabbit antibody (1:1,000, Cat No. P0217, DAKO Cytoma-
tion). Bound antibodies were detected with ECL Plus Western
Blotting Reagent (GE Healthcare) and GelDoc equipment (Bio-
Rad Laboratories).
Proteolysis
Native a-lactalbumin, HAMLET or partially unfolded a-
lactalbumin was subjected to proteolysis in vitro using enzymatic
activities of the 20S proteasome. The protein samples were
dissolved in 10 mM ammonium acetate, pH 7.5. Native a-
lactalbumin was in the presence of 200 mM calcium acetate,
whereas partially unfolded a-lactalbumin was in 200 mM EDTA.
The mixtures were incubated with trypsin (E:S 1:50, by weight)
and chymotrypsin (E:S 1:100, by weight) and degradation was
detected by SDS-PAGE.
Degradation by 20S proteasomes was examined by incubating
HAMLET or partially unfolded EDTA-treated a-lactalbumin
(7 mM) with active 20S proteasomes (BioMol, 6 mg) for 2 hours.
Samples were subsequently separated by SDS-PAGE and proteins
visualized by silver staining. MG132 (Z-Leu-Leu-Leu-CHO, Cat
No. PI102-0005, BioMol) was used to inhibit proteasomes activity.
Enzyme assay of proteasome activity
Chymotrypsin activity was determined using the fluorogenic
substrate Suc-Leu-Leu-Val-Tyr-7-amido-methylcoumarin (suc-
LLVY-AMC, 50 mMt oin vitro experiments and 25 mM to cell
extracts, BioMol) which was added to 200 ng of 20S proteasomes
(BioMol, in 20 mM Tris, pH 7.2, 1 mM EDTA, 1 mM DTT) or
to 10 mg of cell extract (in 20 mM Tris-HCl, pH 7.5). The
reactions were monitored at 37uC at 390/460 nm excitation/
emission wavelengths using a Novostar spectrofluorometer (BMG,
Offenburg, Germany). For in vitro experiments 50 mM of MG132
(Cat No. PI102-0005, BioMol) was used to inhibit proteasomes
activity.
Figure 5. Structural changes in 20S proteasomes after HAMLET treatment in vitro. (A, B) In vitro fragmentation of human 20S proteasomes
after 20 minutes incubation with HAMLET (7 mM), compared to the a-lactalbumin control. (A) The proteins were separated by SDS-PAGE and gels
were stained with Amido black. Changes in 20S proteasome subunits are indicated by arrows. The subunits identified by mass spectrometry are
shown in the table. (B) Western Blot of samples from in vitro mixing experiment with 20S proteasomes and HAMLET or a-lactalbumin using
antibodies against the 20S proteasome core subunits. (C) MALDI-TOF mass spectrometry of intact 20S proteasomes (top panel) and major changes
after HAMLET treatment (bottom panel), indicated by arrows.
doi:10.1371/journal.pone.0005229.g005
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PLoS ONE | www.plosone.org 10 April 2009 | Volume 4 | Issue 4 | e5229Figure 6. Changes in 20S proteasome staining after HAMLET treatment of carcinoma cells. (A–C) Changes in the staining of 20S
proteasome subunits in A549 cells after HAMLET treatment (34 and 45 mM, 1 hour). Cells were stained with antibodies against the 20S proteasome
core subunits (a5, a7, b1, b5, b5i and b7), antibodies against the b1 subunit or antibodies against the b5 subunit. (A) Confocal images showing
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In vitro mixing of HAMLET with 20S proteasomes.
HAMLET or a-lactalbumin (7 mM) were mixed with 6 mgh u m a n
erythrocyte 20S proteasomes (BioMol) in 20 ml reaction buffer
(20 mMTris,pH 7.2,1 mMEDTA,1 mMDTT)andincubatedfor
20 minutes at 37uC. The proteins were separated by SDS-PAGE
(NuPAGE 12% Bis-Tris or 4–12% Bis-Tris gels, Invitrogen) and
stained with Amido black. Separate gels were blotted to PVDF-Plus
membranes (GE Osmonics). Membranes wereblocked with 2% BSA
and incubated with polyclonal rabbit antibodies against the core
subunits (a5, a7, b1, b5, b5i and b7) of the 20S proteasome (1:500,
Cat No. PW8155, BioMol) and HRP-conjugated goat anti-rabbit
antibodies (1:500, DAKO Cytomation). Bound antibodies were
detected with ECL Plus Western Blotting Reagent (GE Healthcare)
and GelDoc equipment (Bio-Rad Laboratories).
20S proteasome detection in cell extracts. Cell extracts
were denatured, separated by SDS-PAGE (NuPAGE, 4–12% Bis-
Tris gels, Invitrogen) and blotted onto PVDF-Plus membranes
(GE Osmonics). Membranes were blocked with 5% non-fat dried
milk and incubated with polyclonal rabbit antibodies against the
core subunits (a5, a7, b1, b5, b5i and b7) of the 20S proteasome
(Cat No. PW8155, BioMol) and HRP-conjugated swine anti-
rabbit secondary antibody (Cat No. P0217, DAKO Cytomation).
Bound antibodies were detected with ECL Plus Western Blotting
Reagent (GE Healthcare) and GelDoc equipment (Bio-Rad
Laboratories).
Preparation of cell extracts
10
6 A549 cells were treated with 34 mM HAMLET in 24-well
culture plates (TPP). For proteasome inhibition, cells were pre-
incubated for 1 hour with 5 mM of the reversible proteasome
inhibitor MG132 (Cat No. PI102-0005, BioMol). After treatment,
cells were detached with Versene buffer (140 mM NaCl, 2.4 mM
KCl, 8 mM Na2HPO4, 1.6 mM KH2PO4, 0.5 mM EDTA,
pH 7.2), collected by centrifugation (4006g, 8 minutes) and lysed
in ice-cold NP-40 buffer (20 mM Tris-HCl, pH 8.0, 100 mM
NaCl, 1 mM EDTA, 0.5% NP-40) supplemented with Complete
protease inhibitor cocktail (Roche Diagnostics). The DC protein
assay (BioRad) was used to quantify total protein concentration.
Matrix-assisted laser desorption ionization, time-of-flight
(MALDI-TOF) mass spectrometry
After in vitro mixing of HAMLET and human erythrocyte 20S
proteasomes (BioMol) mixtures were separated by SDS-PAGE (see
details above). Bands of interest were excised, trypsinized and
further analyzed by mass spectrometry using a M@LDITM-LR
HT instrument (Micromass, Manchester, UK) and the MASCOT
search engine. MALDI-TOF mass spectrometry was also
performed on the HAMLET and proteasome mixtures without
previous SDS-PAGE or trypsinization. For protein analysis mass
spectra were calibrated externally and for peptide analysis internal
calibration from trypsin autolysis peaks was used. Peptides were
further analyzed with FindPept (http://www.expasy.ch/tools/
findpept.html).
Statistical analysis
Groups were compared with Student’s t-test.
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